{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:55:36Z","timestamp":1770814536263,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ontario Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>(1) Background: To make recommendations on the most effective therapy options for Ductal Carcinoma of the Breast (DCIS) patients; (2) Methods: MEDLINE, EMBASE, Cochrane Library, PROSPERO databases, and main relevant guideline websites were searched. Draft versions of the guideline went through formal internal and external reviews, with a final approval by the Program in Evidence Based Care and the DCIS Expert Panel. The Grading of Recommendations, Assessment, Development, and Evaluation approach was followed; (3) Results: Based on the current evidence from the systematic review and this guideline authors\u2019 clinical opinions, initial draft recommendations were developed to improve the management of patients with DCIS. After a comprehensive internal and external review process, ten recommendations and 27 qualifying statements were eventually made. This guideline includes recommendations for the primary treatment of DCIS with surgical treatment and\/or radiation therapy and the management of DCIS after primary treatment for patients with DCIS, including DCIS with microinvasion (&lt;1 mm through the duct); (4) Conclusions: The current guideline was created after a systematic review and a comprehensive internal and external review process. We believe this guideline provides valuable insights that will be useful in clinical decision making for health providers.<\/jats:p>","DOI":"10.3390\/curroncol31120569","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T09:30:18Z","timestamp":1733391018000},"page":"7738-7753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-2199","authenticated-orcid":false,"given":"Muriel","family":"Brackstone","sequence":"first","affiliation":[{"name":"London Health Sciences Centre-London Regional Cancer Program, Victoria Hospital, 800 Commissioners Road East, London, ON N6A 5W9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Durocher-Allen","sequence":"additional","affiliation":[{"name":"Program in Evidence-Based Care, Ontario Health (Cancer Care Ontario), 699 Concession Street, Hamilton, ON L8V 1C3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Califaretti","sequence":"additional","affiliation":[{"name":"Grand River Regional Cancer Centre, 835 King Street W, Kitchener, ON N2G 1G3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre-Medical Oncology, T2-038-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Knowles","sequence":"additional","affiliation":[{"name":"Department of Surgery, St Joseph\u2019s Health Care Centre, 268 Grosvenor Street, London, ON N6A 4V2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Salim","sequence":"additional","affiliation":[{"name":"Patient and Family Advisor, Ontario Health, 500-525 University Ave, Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taude","family":"Plexman","sequence":"additional","affiliation":[{"name":"Patient and Family Advisor, Ontario Health, 500-525 University Ave, Toronto, ON M5G 2L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Anne","family":"Koch","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jncimonographs\/lgq027","article-title":"Epidemiology of ductal carcinoma in situ","volume":"2010","author":"Kerlikowske","year":"2010","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2017124","DOI":"10.1001\/jamanetworkopen.2020.17124","article-title":"Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer","volume":"3","author":"Giannakeas","year":"2020","journal-title":"JAMA Network Open"},{"key":"ref_3","unstructured":"Shelley, W., McCready, D., Holloway, C., Trudeau, M., Sinclair, S., and Breast Cancer Disease Site Group (2024, October 29). Management of Ductal Carcinoma In Situ of the Breast; Toronto (ON): Cancer Care Ontario; 19 September 2006 [In review Jan 2014]. Program in Evidence-based Care EvidenceBased Series No.: 1\u201310 Version 2.2006 IN REVIEW. Available online:  https:\/\/citeseerx.ist.psu.edu\/document?repid=rep1&type=pdf&doi=02deec396d8a8027836ad2c128e97e611f359e86."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","article-title":"The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation","volume":"13","author":"Browman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1200\/JCO.1998.16.3.1226","article-title":"Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback","volume":"16","author":"Browman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_6","unstructured":"Brackstone, M., Durocher-Allen, L.D., Califaretti, N., Eisen, A., Knowles, S., Salim, A., and Plexman, T. (2024). Management of Ductal CArcinoma in Situ of the Breast, Program in Evidence-Based Care Guideline No.: 1\u201310 Version 4; Ontario Health (Cancer Care Ontario). Available online: http:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: Advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"Can. Med. Assoc. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/tbj.12889","article-title":"Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials","volume":"24","author":"Garg","year":"2018","journal-title":"Breast J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4103\/jcrt.JCRT_160_19","article-title":"Comparison of local recurrence after mastectomy for pure ductal carcinoma in situ with close or positive margins: A meta-analysis","volume":"16","author":"Kim","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1245\/s10434-016-5446-2","article-title":"The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis","volume":"23","author":"Marinovich","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s12253-018-0553-y","article-title":"Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): A Meta-Analysis","volume":"26","author":"Yan","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Shumway, D.A., Corbin, K.S., Farah, M.H., Viola, K.E., Nayfeh, T., Saadi, S., Shah, V., Hasan, B., Shah, S., and Mohammed, K. (2023). AHRQ Comparative Effectiveness Reviews. Partial Breast Irradiation for Breast Cancer, Agency for Healthcare Research and Quality (US).","DOI":"10.23970\/AHRQEPCCER259"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2006.06.1366","article-title":"Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853\u2014A study by the EORTC breast cancer cooperative group and EORTC radiotherapy group","volume":"24","author":"Bijker","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.radonc.2021.09.014","article-title":"Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ","volume":"164","author":"Bourgier","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3\u201307\/TROG 07.01): A randomised, factorial, multicentre, open-label, phase 3 study","volume":"400","author":"Chua","year":"2022","journal-title":"The Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","article-title":"Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial","volume":"31","author":"Donker","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/02841860600681569","article-title":"SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening","volume":"45","author":"Emdin","year":"2006","journal-title":"Acta Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2007.12.7969","article-title":"Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast","volume":"26","author":"Holmberg","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Leonard, C.E., Tole, S.P., Turner, M.P., Bennett, J.P., Howell, K.T., and Carter, D.L. (2021). Association of the 12-Gene Breast DCIS Score Assay With Local Recurrence in Patients With Ductal Carcinoma In Situ Treated on Accelerated Partial Breast Radiotherapy Protocols. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.671047"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-021-06278-5","article-title":"Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?","volume":"189","author":"Hampton","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","article-title":"Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Margolese","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","article-title":"RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation","volume":"33","author":"McCormick","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology\/RTOG 9804","volume":"39","author":"McCormick","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"PD15-07","DOI":"10.1158\/1538-7445.SABCS22-PD15-07","article-title":"PD15-07 7-gene predictive biosignature improves risk stratification for breast ductal carcinoma in situ patients compared to clinicopathologic criteria, identifying a low risk group not clinically benefiting from adjuvant radiotherapy","volume":"83","author":"Rabinovitch","year":"2023","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"djw256","DOI":"10.1093\/jnci\/djw256","article-title":"Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ","volume":"109","author":"Rakovitch","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e076022","DOI":"10.1136\/bmj-2023-076022","article-title":"Association of DCIS size and margin status with risk of developing breast cancer post-treatment: Multinational, pooled cohort study","volume":"383","author":"Schmitz","year":"2023","journal-title":"BMJ"},{"key":"ref_30","unstructured":"Sestak, I., Cuzick, J., Bonanni, B., Bundred, N., Levy, C., Sibylle, L., Neven, P., Stierer, M., Holcombe, C., and Coleman, R. (2020, January 8\u201311). 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/SLA.0000000000002439","article-title":"Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation","volume":"269","author":"Tadros","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial","volume":"32","author":"Warnberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Warnberg, F., Karlsson, P., Holmberg, E., Sandelin, K., Whitworth, P.W., Savala, J., Barry, T., Leesman, G., Linke, S.P., and Shivers, S.C. (2021). Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (Dcis) of the breast, in a randomized clinical trial (swedcis). Cancers, 13.","DOI":"10.2139\/ssrn.3869642"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/0284186X.2023.2245552","article-title":"Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS)","volume":"62","author":"Warnberg","year":"2023","journal-title":"Acta Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: A new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Haviland","year":"2020","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"GS4-04","DOI":"10.1158\/1538-7445.SABCS18-GS4-04","article-title":"Primary results of NSABP B-39\/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer","volume":"79","author":"Vicini","year":"2019","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0140-6736(19)32515-2","article-title":"External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): A randomised controlled trial","volume":"394","author":"Whelan","year":"2019","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prro.2016.09.007","article-title":"Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement","volume":"7","author":"Correa","year":"2017","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline","volume":"14","author":"Shaitelman","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/12\/569\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:45:30Z","timestamp":1760114730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/12\/569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["curroncol31120569"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31120569","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}